Findings: FDA warnings and consensus recommendations have not increased testing for glucose levels and lipid profiles in Medicaid patients starting second-generation antipsychotics.
Data Source: Retrospective, population-based case-control study of data on 312,978 patients receiving Medicaid in three states.
Disclosures: Funded by Pfizer, which makes ziprasidone. The investigator has received research funds from Eli Lilly, maker of olanzapine. Several other investigators have received funding from or been consultants to those and other companies that make second-generation antipsychotics.
PREVIEW